Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesity, with a consistent safety profile.
Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery

Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery

Researchers developed and validated the FMO score, a noninvasive, cost-effective tool to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) in obese patients, showing strong predictive performance across multiple international cohorts.